Genprex to Present at Upcoming Investor Conferences
Genprex, Inc. (NASDAQ: GNPX), a clinical stage gene therapy company developing a new approach to treating cancer based upon a novel proprietary technology platform, announced today that company management will present at the following upcoming investor and industry conferences:
Event: H.C. Wainwright 20th Annual Global Investment Conference |
Date: September 6, 2018 |
Time: 5:30 PM EDT |
Location: New York, NY |
Presenter: Dr. Julien Pham, President and COO |
Event: Newsmakers in the Biotech Industry |
Date: September 7, 2018 |
Time: 1:30 PM EDT |
Location: New York, NY |
Presenter: Dr. Julien Pham, President and COO |
About Genprex, Inc.
Genprex, Inc. is a clinical stage gene therapy company developing a new approach to treating cancer, based upon a novel proprietary technology platform, including Genprex’s initial product
candidate, Oncoprex™ immunogene therapy for non-small cell lung cancer (NSCLC). Genprex’s platform technologies are designed to administer cancer fighting genes by encapsulating them into nanoscale
hollow spheres called nanovesicles, which are then administered intravenously and taken up by tumor cells where they express proteins that are missing or found in low quantities. Oncoprex has a
multimodal mechanism of action whereby it interrupts cell signaling pathways that cause replication and proliferation of cancer cells, re-establishes pathways for apoptosis, or programmed cell
death, in cancer cells, and modulates the immune response against cancer cells. Oncoprex has also been shown to block mechanisms that create drug resistance. Visit the company’s web site at www.genprex.com or follow Genprex on Twitter at https://twitter.com/genprex and Facebook at https://www.facebook.com/genprexinc/.
Lesen Sie auch
View source version on businesswire.com: https://www.businesswire.com/news/home/20180821005237/en/